中线导管用于血管加压药治疗的临床应用研究
该研究采用方便抽样法纳入山西省汾阳医院呼吸重症监护病房(RICU)2022年6月至2023年6月使用血管加压药的88例成人患者,2022年6—12月经PICC输注的44例为PICC组,2023年1—6月经中线导管输注的44例为中线导管组,两组均在B超引导下采用改良Sedinger技术穿刺置管,选用肘窝与腋窝之间中1/3部位、5 Fr双腔导管。置管后随访至拔管、死亡或30天(以先发生者为准),依据美国输液护士学会(INS)修订的《输液治疗实践标准》并结合前期预试验结果进行安全性评价。结果显示两组均未发生CRBSI和静脉炎,穿刺点渗液均为2.27%(1/44);中线导管组导管不完全堵塞、拔管时导管内血栓、穿刺点发红(但无感染)发生率分别为4.55%(2/44) vs 6.82%(3/44)、0%(0/44) vs 2.27%(1/44)、0%(0/44) vs 4.55%(2/44),总体并发症发生率显著降低[6.82%(3/44) vs 15.91%(7/44),P<0.01]。作者认为经中线导管给予血管加压药可减少导管相关并发症、降低中心静脉置管率并减轻患者经济负担。
要点
- RICU使用血管加压药的成人患者经中线导管(5 Fr双腔,B超引导下改良Sedinger技术,肘窝与腋窝之间中1/3部位)输注,总体导管相关并发症发生率6.82%(3/44) vs PICC组15.91%(7/44),P<0.01。
- 两组CRBSI和静脉炎发生率均为0,穿刺点渗液均为2.27%(1/44);中线导管组导管不完全堵塞4.55%(2/44) vs PICC组6.82%(3/44)。
- 中线导管组拔管时导管内血栓0%(0/44) vs PICC组2.27%(1/44),穿刺点发红(但无感染)0%(0/44) vs 4.55%(2/44)。
- 两组性别、年龄、导管留置时间和原发疾病无统计学差异,基线均衡可比。
- 作者认为经中线导管给予血管加压药可降低导管相关并发症发生率、减少中心静脉置管率并减轻患者经济负担。
适用人群与场景
- 山西省汾阳医院呼吸重症监护病房(RICU)2022年6月至2023年6月收治的88例使用血管加压药的成人患者。
- 2022年6—12月经PICC输注血管加压药的44例为PICC组,2023年1—6月经中线导管输注血管加压药的44例为中线导管组。
处置流程与药物剂量
- 两组均在B超引导下采用改良Sedinger技术穿刺置管,选择肘窝与腋窝之间的中1/3部位,使用5 Fr双腔导管。
- 置管后随访至拔管、死亡或30天(以先发生者为准)。
- 依据美国输液护士学会(INS)修订的《输液治疗实践标准》并结合前期预试验结果,对导管不完全堵塞、CRBSI、静脉炎、拔管时导管内血栓、穿刺点发红(但无感染)、穿刺点渗液进行安全性评价。
研究设计与关键结果
- 研究类型为方便抽样法对照研究,纳入88例成人患者,PICC组44例、中线导管组44例;两组性别、年龄、导管留置时间和原发疾病无统计学差异。
- 置管后观察期内两组均未发生CRBSI和静脉炎;穿刺点渗液两组均为2.27%(1/44)。
- 导管不完全堵塞:中线导管组4.55%(2/44) vs PICC组6.82%(3/44);拔管时导管内血栓:中线导管组0%(0/44) vs PICC组2.27%(1/44);穿刺点发红(但无感染):中线导管组0%(0/44) vs PICC组4.55%(2/44)。
- 总体并发症发生率:中线导管组6.82%(3/44) vs PICC组15.91%(7/44),P<0.01。
证据类型、等级与局限
- 证据类型:方便抽样法对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,经中线导管给予血管加压药可减少导管相关并发症、降低中心静脉置管率并减轻患者经济负担。
指南或共识出处
- 美国输液护士学会(INS)修订的《输液治疗实践标准》(原文引用作为安全性评价依据)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the safety and necessity of vasopressor infusion through midline catheter.
METHODS: A convenient sampling method was used for a controlled study. A total of 88 adult patients who used vasopressors admitted to respiratory intensive care unit (RICU) of Fenyang Hospital in Shanxi Province from June 2022 to June 2023 were enrolled as the research subjects. A total of 44 patients who were infused with vasopressors through peripherally inserted central venous catheter (PICC) from June to December 2022 were enrolled as the PICC group, and 44 patients who were infused with vasopressors through midline catheter from January to June 2023 were enrolled as the midline catheter group. Both groups of patients used the modified Sedinger technique under the guidance of B-ultrasound for puncture and catheter placement. The middle 1/3 site between the cubital fossa and the axilla was selected. The catheters were 5 Fr double lumen. After catheter placement, the patients were followed until catheter removal, death, or 30 days (whichever came first). Based on the Infusion therapy standards of practice revised by American Infusion Nurses Society (INS), and combined with the results of previous preliminary tests, the safety evaluation was conducted on incomplete catheter obstruction, catheter-related bloodstream infection (CRBSI), phlebitis, thrombus within the catheter during extubation, redness of the puncture site (but no infection), and exudation of the puncture site in the two groups of patients.
RESULTS: There were no statistical differences in gender, age, catheter indwelling time, and primary disease between the two groups, indicating that the baseline data of the two groups were balanced and comparable. No CRBSI or phlebitis occurred in both groups during the observation period after catheterization. One patient in both groups had exudation at the puncture site [both were 2.27% (1/44)]. Compared with the PICC group, the incidence of incomplete catheter obstruction, thrombus within the catheter during extubation, redness of the puncture site (but no infection) in the midline catheter group were lowered [incomplete catheter obstruction: 4.55% (2/44) vs. 6.82% (3/44), thrombus within the catheter during extubation: 0% (0/44) vs. 2.27% (1/44), redness of the puncture site (but no infection): 0% (0/44) vs. 4.55% (2/44)], the overall incidence was significantly decreased [6.82% (3/44) vs. 15.91% (7/44), P < 0.01].
CONCLUSIONS: Administering vasopressor through a midline catheter can reduce the incidence of catheter-related complications, decrease the rate of central venous catheterization, and reduce the financial burden on patients.
参考来源
- Guo R, Wu J, Ren X, et al. [Clinical application study of midline catheter in vasopressor therapy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39223893. doi:10.3760/cma.j.cn121430-20240326-00286
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。